[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-chronic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,71,98,121,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100639258","a-study-of-acupuncture-for-treating-asthma-100639258",false,"NCT07611955","A Study of Acupuncture for Treating Asthma","The Effects of Acupuncture on Patients With Chronic Asthma: a Multicenter, Randomized, Three-arm, Sham-controlled Superiority Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for asthma, and be in the chronic persistent phase with mild to moderate disease severity, referring to the grading criteria of the Guidelines for the Prevention and Treatment of Asthma (2024 Edition).\n* Aged 18 to 70 years, regardless of gender.\n* Asthma Control Test (ACT) score≤19 points (poorly controlled or very poorly controlled asthma).\n* Maintain a stable asthma treatment regimen for at least 4 weeks before enrollment.\n* Clear thinking and consciousness, coherent responses, able to understand the items of various scales and complete the assessment.\n* Volunteer to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Complicated with severe mental illnesses (such as uncontrolled schizophrenia, acute phase of bipolar disorder, etc.) or moderate to severe cognitive impairment (such as dementia), resulting in inability to understand the research process or cooperate with efficacy evaluation.\n* A history of substance\u002Falcohol dependence within the past 12 months.\n* Complicated with other physical diseases that may cause depressive symptoms (such as hypothyroidism, chronic pain syndrome, malignant tumors, rheumatoid arthritis, etc.).\n* Received antidepressant drug treatment within the past 6 months.\n* Suffering from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, etc.\n* Complicated with other cancers or relatively severe chronic diseases of the heart, liver, kidneys, etc.\n* Received acupuncture treatment within the past 3 months.\n* Pregnant or lactating women.","ALL","18 Years","70 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Asthma is a common chronic respiratory disease with a low clinical control rate, highlighting the need for novel therapeutic strategies. Recurrent asthma attacks emotional symptoms, such as anxiety and depression, etc. On the contrary, symptoms such as anxiety and depression worsen asthma control. Acupuncture is commonly applied as an effective traditional Chinese medical therapy for asthma. Acupoints GV14, BL13 and BL12 are adopted for the intervention of asthma. GV20 and GV29 are selected to improve emotional symptoms including depression. Nevertheless, standardized therapeutic regimens of acupuncture for asthma and its concomitant emotional symptoms are still lacking. 180 patients with mild to moderate asthma will be recruited in this multicenter randomized controlled trial, randomly assigned to the true acupuncture group, sham acupuncture group and usual care group. The primary outcome is the score of the Asthma Control Test (ACT). Secondary outcomes include the Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), pulmonary function, and fractional exhaled nitric oxide (FeNO). The superiority of combined acupuncture therapy in improving asthma control, relieving negative emotions, and enhancing quality of life is to be verified in this study, with high quality evidence for acupuncture treatment of asthma thereby to be provided.",[27,28,29],"Asthma Chronic","Asthma (Diagnosis)","Asthma","NOT_YET_RECRUITING","2026-05-28",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":21},"2026-05-21",{"date":38,"type":21},"2028-09",{"name":40,"class":41},"Shanghai University of Traditional Chinese Medicine","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100632356","asthma-ctrl-smart-trial-100632356","NCT07512622","Asthma Ctrl SMART Trial","Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents With Asthma.","Inclusion Criteria:\n\n* Patient age between 12-18 years\n* Patient is diagnosed with severe-persistent or moderate-persistent asthma per NAEPP asthma guidelines\n* Patient is prescribed at least one daily inhaled controller medication or a daily combination inhaled corticosteroid and long-acting beta-agonist and a beta-agonist bronchodilator\n* English fluency for patient, caregiver, and clinician\n\nExclusion Criteria:\n\n* Significant cognitive deficits that may interfere with comprehension per medical team or chart review\n* Diagnosis of serious mental illness (e.g., schizophrenia)\n* Diagnosis of pervasive developmental disorder\n* Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis, pulmonary hypertension, and moderate or severe tracheomalacia)\n* Patient receives school administered daily controller medication at the time of the enrollment visit","12 Years",{"count":51,"type":21},389,[24],"The primary objective is to examine the efficacy of an mHealth adherence intervention (Asthma Ctrl) on adherence to daily inhaled corticosteroids as measured by electronically monitored adherence in adolescents with asthma. The secondary objective is to compare the effectiveness of three intervention strategies: 1. asthma management app (control); 2. Asthma Ctrl; 3. Asthma Ctrl+ on adherence, lung function, and health care utilization at post-intervention and 1- and 6-month follow-up. The third objective is to explore and contrast different challenges and combinations of challenges to identify which are most impactful in determining response to the three intervention strategies.",[55,27],"Asthma in Children",[57,58,59,60],"sequential, multiple assignment, randomized trial (SMART)","adherence","asthma","adolescents","2026-05-08",{"date":63,"type":34},"2026-05-11",{"date":65,"type":21},"2026-05-30",{"date":67,"type":21},"2030-06-01",{"name":69,"class":41},"Children's Hospital Medical Center, Cincinnati",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100561926","improving-the-quality-of-care-for-asthma-patients-at-risk-of-exacerbations-100561926","NCT06596512","Improving the Quality of Care for Asthma Patients at Risk of Exacerbations","iCARE","Inclusion Criteria:\n\n* Clinician diagnosis of asthma for ≥1 year;\n* Age at enrollment--18-75 years old inclusive;\n* One or more AEXs that occurred \\< 12 months prior to enrollment. An AEX is defined as an asthma deterioration that either requires 72 hours or more of an oral or parenteral steroids OR a hospital stay for more than 24 hours for asthma. In the case of patients on biologics for asthma, the exacerbation must have also occurred after at least 6 months of biologic therapy;\n* Currently prescribed an ICS\u002FLABA containing preparation containing at least the lowest dose of ICS described in Table 2 as regular daily maintenance therapy for at least one month;\n* Has a rescue SABA containing inhaler that they have used on average at least once a month.\n* Able to provide consent in English for the feasibility study or in English or Spanish for the full study.\n\nExclusion Criteria:\n\n* Life expectancy \\<2 years;\n* COPD diagnosis unless: a) they were a never smoker; OR b) former smoker with normal pulmonary function tests (PFT; FEV1\u002FFVC ratio of \\>70%); OR c) current smoker with normal PFTs within 24 months of enrollment; OR d) current or former smoker with obstruction on PFTs (FEV1\u002FFVC ratio of \\<70% but who demonstrates BOTH \\>12% acute bronchodilator reversibility AND a normal diffusing capacity both within 24 months of enrollment (criteria successfully used in PREPARE);\n* Use of single inhaler product that contains an ICS, LAMA and LABA or one containing both LABA and LAMA within 1 month of enrollment;\n* Use of current biologic for less than 6 months;\n* Known allergy to any of the components of the intervention;\n* Coexisting lung disease (e.g. Cystic Fibrosis, connective tissue disease (unless asthma preceded diagnosis of connective tissue disease by at least 2 years), prematurity-born at 32 weeks or sooner, organ transplantation, bronchiectasis, sarcoid, and obliterative bronchiolitis, among others)\n* Has been in an asthma drug treatment trial in past 60 days or within 5 half-lives, whichever is longer, prior to study visit.\n* Living in household with someone already enrolled in the study.\n* Using daily or every other day oral corticosteroids for asthma or any other condition\n* An AEX in the prior 4 weeks\n* History of bronchial thermoplasty in prior 6 months\n* Poorly or uncontrolled atrial fibrillation\n* Not on stable asthma medications for at least 1 month prior to enrollment\n* Using doses of ICS\u002FLABA lower than the minimum below:\n* Budesonide 320 ug,\n* Fluticasone Advair Diskus\u002F Wixela 200-250 ug Advair HFA 180-230ug Airduo 110-113 ug Breo 100 ug\n* Mometasone 200 ug","75 Years",{"count":80,"type":21},4100,[24],"The goal of this trial test two known effective asthma strategies. Treatment guidelines recommend combination therapy of inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA) inhaled medications. This strategy is known as MART (maintenance and reliever therapy). The second strategy is PARTICS (patient activated reliever triggered ICS) strategy instructs patients to use an ICS metered dose inhaler (ICS) each time they use their rescue inhaler. In addition, they are instructed to take 5 puffs of the ICS after each rescue nebulizer use. PARTICS has been shown to reduce exacerbations, increase asthma control and quality of life, however, the question remains if PARTICS is as effective as MART and therefore be an alternative to MART. This trial will test PARTICS and MART head-to-head.\n\nThe trial will include adults with moderate-to-severe asthma at risk for an asthma exacerbation, currently using a combination ICS.\n\nThe main questions aim to answer:\n\n* Is PARTICS as effective as SMART?\n* Might PARTICS be more effective than SMART? Is the relative effectiveness of PARTICS versus SMART affected by frequent nebulizer use for asthma relief?\n* Do PARTICS and SMART diverge in terms of their effectiveness on differing asthma outcomes important to patients?\n* Do socioeconomic factors affect the relative effectiveness of PARTICS and SMART? Researchers will compare non frequent nebulizer (NFN) users - less than once a week to frequent nebulizer users - once a week or more, to assess whether the PARTICS strategy is ono-inferior (or superior to the MART strategy in reducing exacerbations, (primary outcome), increasing asthma control and quality of life and decrease days lost from work\u002Fschool or usual activities.\n\nMost participants will be consented, enrolled, and randomized virtually, others will be consented, enrolled and randomized in person. Once randomized they will be instructed on how to use the prescribed medication:\n\n* Participants randomized to MART will be instructed to use the prescribed ICS\u002FLABA for maintenance and as needed for rescue.\n* Participants randomized to PARTICS will be instructed to use the prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.\n* Participants will be followed for 16 months by monthly survey.",[29,27,84,85],"Asthma Severe Persistent With Exacerbation","Asthma Moderate Persistent With Exacerbation",[87,88,76],"ICS reliever therapy","Decrease exacerbations","2026-03-10",{"date":91,"type":34},"2026-03-12",{"date":93,"type":21},"2026-07",{"date":95,"type":21},"2030-12",{"name":97,"class":41},"Brigham and Women's Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100537072","phase-2-metformin-in-asthma-for-overweight-and-obese-individuals-mina-100537072","NCT06273072","Metformin IN Asthma for Overweight and Obese Individuals (MINA)","Inclusion Criteria:\n\n* Physician-diagnosed asthma on maintenance therapy\n* Not well-controlled asthma (ACT score \\\u003C20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)\n* Overweight or obesity: Body mass index ≥25kg\u002Fm2\n* Adult: Age ≥18\n\nExclusion Criteria:\n\n* Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding\n* Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months\n* Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis\n* Active smoking or former smoker with ≥20 pack-year smoking history\n* Chronic kidney disease: estimated glomerular filtration rate ≤60 mL\u002Fmin\u002F1.73 m2\n* Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man\n* Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2x the upper limit of normal or prior diagnosis of liver disease\n* Anemia: hemoglobin \\\u003C 13 g\u002Fdl in males and hemoglobin \\\u003C 11 g\u002Fdl in females\n* Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss\n* Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)\n* Participation in any other clinical trial (observational studies are permitted)",{"count":105,"type":21},100,[107],"PHASE2","This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.",[29,27,110],"Overweight and Obesity","RECRUITING","2026-01-15",{"date":114,"type":34},"2026-01-16",{"date":116,"type":34},"2024-12-09",{"date":118,"type":21},"2028-12-31",{"name":120,"class":41},"Johns Hopkins University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100545088","remote-patient-monitoring-solution-for-chronic-respiratory-disease-management-100545088","NCT06377345","Remote Patient Monitoring Solution for Chronic Respiratory Disease Management","Inclusion Criteria:\n\n* Diagnosis of asthma\n* Pediatric patients (age 7 to 17), adult patients (age 18 and above\n* Have an asthma exacerbation on the day of visit\n* Be willing to use the AeviceMD device\n* Has a smart phone to download the application that is paired with Aevice\n* Has wireless fidelity (WIFI) connection to use with Aevice\n* English speaking\n\nExclusion Criteria:\n\n* No capacity for consent\n* Concurrent chronic obstructive pulmonary disease (COPD)","7 Years","90 Years",{"count":20,"type":21},[24],"Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.\n\nMethodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.\n\nImportance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.\n\nPotential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.",[29,133,55,134,27],"Asthma Attack","Asthma Acute","2025-05-12",{"date":137,"type":34},"2025-05-15",{"date":139,"type":34},"2024-05-01",{"date":141,"type":21},"2025-12-30",{"name":143,"class":41},"SingHealth Polyclinics",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":144},"100483218","feasibility-of-a-smartphone-application-for-asthma-self-management-100483218","NCT05572177","Feasibility of a Smartphone Application for Asthma Self-management","Feasibility of MHealth Technology for Improving Self-Management and Adherence Among Asthmatic Adolescents","Inclusion Criteria:\n\n* At least 12 and less than 18 years at enrollment\n* Established mild, moderate, or severe persistent asthma with a diagnosis verified by clinic physicians\n* Speak English\n* Not planning on moving out of the Tampa Bay area during the trial period\n* Must have a suitable iPhone or Android device available to use with the app\n\nExclusion Criteria:\n\n* Having mental or other development disorder that may make self-management of a chronic condition difficult\n* Having other chronic lung disease or one or more of the following disorders including cystic fibrosis, neuromuscular disease, immunodeficiency or autoimmune disorders, blindness or severe vision impairment that may interfere with the ability to use the mobile app\n* Having participated in the app development phase of the funded project","17 Years",{"count":154,"type":21},50,[24],"The primary goal of this project is to determine the feasibility, acceptability, and adherence of a smartphone application for improving asthma self-management in a pilot randomized controlled trial (RCT). The app is specifically designed to appeal to adolescents. Adolescents with persistent asthma will be randomized to receive: 1) standard-of-care or 2) the self-management app in addition to standard-of-care. Feasibility will be assessed by the ability to recruit and retain subjects, technical barriers to implementation, and the appropriateness of the intervention among adolescents and providers. The acceptability of the intervention will be determined by appraising perceived usefulness, entertainment, and ease of use of the app. Adherence to usage of the app over a 6-month period will be assessed by examining the frequency of app usage and the features that were used, and the extent of data regarding self-management that was entered. A secondary objective is to obtain preliminary estimates of effectiveness of the app on clinical outcomes (ACT score, spirometry, CHSA-C, exacerbations, and medication adherence) relative to standard-of-care. It is hypothesized that the app will result in a high level of adherence and will be a feasible and acceptable intervention to improve self-management among adolescents with persistent asthma.",[27],"2024-09-30",{"date":160,"type":34},"2024-10-02",{"date":162,"type":34},"2023-06-26",{"date":164,"type":21},"2025-07-31",{"name":166,"class":41},"University of South Florida"]